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from ROD. In classification, a 65% sensitivity and specificity are found. 
Data will also be presented on the CHR group and their alignment, 
together with VBM analysis for structural MRI examining correlates with 
highly weighted classifying symptoms in and across all three groups.
Discussion: When given early in the course of illness, interventions have the 
greatest potential impact, and characterization and accurate diagnosis of 
depression in emerging mental disorders is an important goal. This study 
suggests it may be possible to accurately identify depression in different 
diagnostic categories, including major depressive disorder, psychosis and 
clinical high risk, and that neuroimaging holds potential to add to diagnos-
tic accuracy in complex co-morbid disorders.
S14. DNA METHYLATION CHANGES IN 
GABAERGIC AND GLUTAMATERGIC MARKERS 
IN EARLY SCHIZOPHRENIA
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Paulo Rossi Menezes2, Paulo Louzada Jr2, Caroline Dalton1, 
Cristina Marta Del-Ben2, Gavin Reynolds1
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Background: GABAergic and glutamatergic systems play an important 
role in the neurobiology of  schizophrenia, and changes in their markers 
are reported in both postmortem human brain and in animal models. 
Recent studies have demonstrated that abnormalities in DNA methyl-
ation may underlie the alterations in various indicators of  GABAergic 
and glutamatergic functions in schizophrenia. As our group previously 
found decreased NR2 protein plasma levels and downregulation of  par-
valbumin (PVALB) mRNA in first episode of  psychosis (FEP) patients, 
we hypothesised that changes in DNA methylation may be responsible 
for these indicators of  glutamatergic and GABAergic deficits in FEP 
patients.
Methods: Blood samples were collected from patients in FEP (n = 35) after 
their first contact with the mental health assistance, siblings (n = 21) and 
population-based controls (n = 35). Bisulfite conversion and pyrosequenc-
ing were used to determine methylation levels in 4 CpG sites in promoter 
sequence of PVALB and 5 CpG sites at GRIN2B (gene which encodes 
NR2).
Results: We found hypermethylation at a CpG site within the PVALB pro-
moter sequence in patients and their siblings compared to population-
based control group (p< 0.001) while overall hypomethylation was found in 
the 5 CpGs analysed within GRIN2B promoter sequence (p < 0.01).
Discussion: Our PVALB findings are consistent with our previous studies 
showing that PVALB promoter methylation is elevated in schizophrenia 
and, additionally this is the first evidence showing changes in GRIN2B pro-
moter methylation in psychosis. These results together suggest that these 
epigenetic findings may relate to the reduction of protein expression of 
indicators of glutamate and GABA systems seen in this disease.
S15. ABNORMAL EYE TRACKING IN PATIENTS 
WITH SCHIZOPHRENIA UNDER THE SOCIAL 
SCENE
Qijing Bo*,1, Xianbin Li1, Wenlong Jiang1, Changming Wang1, 
Chuanyue Wang1
1Beijing Anding Hospital, Capital Medical University
Background: To investigate whether the eye movement pattern is different 
between facial emotion recognition and real social scene emotion recogni-
tion, and which can better reflect the social function and the clinical symp-
toms using a novel theme identification task.
Methods: Total 29 patients with schizophrenia and 31 healthy controls com-
pleted the theme identification task, in which subjects selected which word, 
out of positive, neutral and negative, described the theme of a picture under 
facial emotion recognition and real social scene emotion recognition. Positive 
and negative syndrome scale (PANSS) and social function in psychosis inpa-
tients (SSPI) were used to assess the symptom and social function.
Results: The schizophrenia’s eye movement paradigms under both facial 
emotion and social scene show decreased number of fixation (t=-3.49, 
P=0.00; t=-3.62, P=0.00), decreased number of saccades (t=-3.15, P=0.00; 
t=-3.72, P=0.00), decreased scan path length (t=-2.23, P=0.03; t=-4.18, 
P=0.03), decreased fixation number in interest area (t=3.01, P=0.00; 
t=-3.24, P=0.00). Different from facial emotion cognition, the eye move-
ment under social scene cognition showed lower percentage of fixation 
number in interest area than that in healthy subjects (P=0.01), furthermore, 
the length of scan path under the negative social scene pictures was associ-
ated with the total score of SSPI (r=-0.38, P=0.04), the PANSS total score 
(r=-0.46, P=0.01), the positive symptoms score (r=-0.39, P=0.04), the gen-
eral score (r=-0.50, P=0.01).
Discussion: The patients showed more abnormal eye tracking indicators 
under social scene than facial emotion. Under negative emotion social 
scene, the length of scan path related to social function and clinical symp-
toms, it may be a potential indicator to evaluate social function and degree 
of disease.
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Background: In terms of response to antipsychotic treatment, patients with 
schizophrenia can be classified into three groups; (1) treatment-resistant patients 
who are clozapine (CLZ)-resistant (ultra treatment-resistant schizophrenia 
[UTRS]), (2) treatment-resistant patients who are CLZ-responsive (TRS), and 
(3) patients who respond to non-CLZ antipsychotics (treatment non-resistant 
schizophrenia [TnRS]). The aim of this study was to examine glutamatergic 
neurometabolite levels in these three patient groups, along with healthy controls 
(HCs), using proton magnetic resonance spectroscopy (1H-MRS).
Methods: Glutamate (Glu) and glutamate+glutamine (Glx) levels were 
assessed in the associative striatum (Str), anterior cingulate cortex (ACC), 
and dorsolateral prefrontal cortex (DLPFC) using 3T 1H-MRS (PRESS, 
TE=35ms). Neurometabolite levels were corrected for cerebrospinal fluid 
proportion.
Results: A total of 100 participants (26 UTRS, 27 TRS, 21 TnRS, and 26 
HCs) were included in this study. Patients with UTRS showed higher Glx 
levels in the ACC compared to HCs (p=0.038). When patients with UTRS 
and TRS were combined into one group, this subset of patients showed 
higher Glu and Glx levels in the ACC compared to HCs (p=0.028 and 
p=0.023, respectively). There were no significant group differences in the 
Str or DLPFC.
Discussion: Previous findings reporting higher glutamatergic levels in the 
ACC of patients with TRS may be mainly influenced by patients with CLZ 
non-responder. Higher ACC glutamatergic neurometabolite level may be a 
biological trait of resistance to the first-line antipsychotic treatment that is 
retained even after CLZ administration.
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